This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: University of Colorado. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Ian Stancil: Innovator in Lung Disease Research
Introduction
Ian Stancil is a notable inventor based in Denver, Colorado, recognized for his contributions to the field of lung disease research. His innovative work focuses on developing methods to better understand and treat fibrotic lung diseases, particularly idiopathic pulmonary fibrosis (IPF).
Latest Patents
Stancil holds a patent for a groundbreaking invention titled "Fibrosis model and methods of use thereof." This patent describes a method for screening test compounds, such as fibrosis or IPF inhibitors, to induce an unjammed-to-jammed transition (UJT) in fibrotic primary human bronchial epithelial cells (HBECs). The process involves culturing these cells at an air-liquid interface to create a differentiated pseudostratified epithelium. By monitoring the motility of the cultured cells, researchers can identify whether the test compound induces the UJT, with stationary cells indicating a successful induction. Additionally, the patent includes methods for identifying lung fibrosis biomarkers.
Career Highlights
Ian Stancil is affiliated with the University of Colorado, where he continues to advance research in lung diseases. His work has significant implications for developing new therapies and understanding the mechanisms underlying fibrosis.
Collaborations
Stancil collaborates with David A. Schwartz, a fellow researcher, to further explore the complexities of lung fibrosis and enhance the impact of their findings in the medical community.
Conclusion
Ian Stancil's innovative contributions to lung disease research, particularly through his patented methods, highlight his commitment to improving patient outcomes in fibrotic lung diseases. His work exemplifies the vital role of inventors in advancing medical science and technology.